Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01746225 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 10, 2012
Results First Posted : March 27, 2020
Last Update Posted : November 17, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Longer first line chemotherapy duration has recently been associated with a modest, but significant improvement in overall survival and a clinically meaningful and statistically significant improvement in progression-free survival, in metastatic breast cancer patients. Prolonging chemotherapy until disease progression, however, must be weighed against the detrimental effects of continuous chemotherapy delivery. The SNAP trial seeks to improve the tolerability of prolonged chemotherapy administration strategy by studying alternative treatment schedules, while preserving and possibly improving treatment efficacy in this disease setting.
The availability of a new nanoparticle albumin-bound taxane, nab-Paclitaxel (Abraxane®), represents an opportunity to test this hypothesis. Nab-Paclitaxel has been developed in an attempt to reduce the toxicity associated with standard taxane administration (caused by the use of chemical solvents) while increasing antitumor efficacy.
The SNAP randomized phase II trial evaluates three schedules of nab-Paclitaxel as prolonged chemotherapy administration strategy. Each of three arms will be compared to a historical reference of seven-month median progression-free survival (PFS) based on the most recent trial with docetaxel as control arm to determine whether any of the three arms are worthy of further investigation.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Metastatic Breastcancer | Drug: nab-Paclitaxel | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 258 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial) |
| Study Start Date : | April 2013 |
| Actual Primary Completion Date : | May 2016 |
| Estimated Study Completion Date : | April 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: A: nab-Paclitaxel 150 mg/m2 days 1,15
Arm A: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity. *Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m². |
Drug: nab-Paclitaxel
Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
Other Name: Abraxane |
|
Experimental: B: nab-Paclitaxel 100 mg/m2 days 1,8,15
Arm B: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity. *Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m². |
Drug: nab-Paclitaxel
Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
Other Name: Abraxane |
|
Experimental: C: nab-Paclitaxel 75 mg/m2 days 1,8,15,22
Arm C: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity. *Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m². |
Drug: nab-Paclitaxel
Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
Other Name: Abraxane |
- Progression-free Survival [ Time Frame: Reported after 18.2 months median follow-up since randomization ]Time from randomization until objective disease progression [progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions] or death, whichever occurs first. For patients without progression, follow-up was censored at the date of last disease assessment without progression, unless death occurred within a short period of time (12 weeks) following the date last known progression-free, in which case the death was counted as a PFS event.
- Feasibility of Treatment: Number of Participants Completed Treatment According to the Protocol for at Least 24 Weeks [ Time Frame: Baseline to 24 weeks follow-up ]Whether or not the patient completed treatment according to the protocol for at least 24 weeks. Patients who progressed within 24 weeks were considered as not completing.
- Disease Control: Overall Response of Stable Disease for a Duration of ≥24 Weeks [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months ]Overall response of stable disease (or non-CR/non-PD for patients with non-measurable disease) for a duration of ≥24 weeks, or better (i.e., partial or complete response) according to RECIST criteria [Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.]
- Best Overall Response [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months ]Best response according to RECIST 1.1 criteria [assessed by MRI] recorded from the start of treatment across all time points until end of study treatment. Confirmation of partial or complete response by an additional scan was not requested in this trial.
- Overall Survival [ Time Frame: Reported after 18.2 months median follow-up since randomization ]Time from randomization until death from any cause, or censored at date last known alive
- Changes in Physical Well-being (Change From Day 1 of Cycle 4 to Day 1 of Cycle 6) [ Time Frame: Assessed from day 1 of cycle 4 through day 1 of cycle 12 ]Primary quality of life=physical well being; endpoint based on the GLQ 8. The indicator was in Linear Analogue Self-Assessment (LASA) format ranging 0-100 (0=as bad as it can be, 100=as good as it can be).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically confirmed HER2-negative metastatic (stage IV) breast cancer.
- Measurable or non-measurable, but radiologically evaluable, disease according to RECIST 1.1 criteria.
- Female aged 18 years or older.
- Life expectancy > 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Either ER-positive or ER-negative disease. Patients with ER-positive disease must be endocrine resistant, defined as having failed at least one prior endocrine therapy for breast cancer, or must be candidates for first-line chemotherapy.
- If previously treated with a taxane or anthracycline in the neoadjuvant or adjuvant setting, the period from end of treatment to disease recurrence must have been > 12 months (> 365 days).
- Radiation therapy, if given and regardless of site, must be completed at least 2 weeks prior to randomization.
- Normal hematologic status.
- Normal renal function.
- Normal liver function.
- Normal cardiac function.
- Women of childbearing potential: documented negative pregnancy test within 2 weeks prior to randomization, and acceptable birth control during the duration of the trial therapy and for a period of 6 months following the last administration of study drug.
- Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to randomization.
- Completed baseline Quality of Life Form.
- The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
- Availability of an formalin fixed paraffin embedded (FFPE) block from the primary tumor (breast lesion) for submission to central pathology review and for translational research.
- Written consent to pathology material submission, signed and dated by the patient and the Investigator prior to randomization.
Exclusion Criteria:
- Any prior chemotherapy for metastatic breast cancer.
- Presence of central nervous system (CNS) metastasis.
- Peripheral neuropathy grade 2 or higher (CTCAE version 4).
- Significant uncontrolled cardiac disease (i.e. unstable angina, recent myocardial infarction within prior 6 months), patients classified as having a New York Heart Association (NYHA) class III or IV congestive heart failure.
- Pregnant or lactating.
- Prior history of non-breast malignancy (except for adequately controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the bladder).
- Any concurrent condition which in the Investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol.
- Contraindications or known hypersensitivity to the study medication or excipients.
- The use of any anti-cancer investigational agents within 30 days prior to expected start of trial treatment.
- Inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01746225
Show 41 study locations
| Study Chair: | Alessandra Gennari, MD | Division of Medical Oncology, E.O. Galliera, Genoa, Italy | |
| Study Chair: | Guy Jerusalem, MD, PhD | CHU Sart Tilman and University of Liège, Liège, Belgium |
Documents provided by ETOP IBCSG Partners Foundation:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | ETOP IBCSG Partners Foundation |
| ClinicalTrials.gov Identifier: | NCT01746225 |
| Other Study ID Numbers: |
IBCSG 42-12 / BIG 2-12 2012-003058-10 ( EudraCT Number ) |
| First Posted: | December 10, 2012 Key Record Dates |
| Results First Posted: | March 27, 2020 |
| Last Update Posted: | November 17, 2022 |
| Last Verified: | November 2022 |
|
Metastatic Breast Cancer HER2-negative Stage IV No previous chemotherapy |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel |
Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |